Commitments and Contingencies - Additional Information (Details)						1 Months Ended				3 Months Ended
	Jan. 14, 2022 USD ($)	Oct. 12, 2021 USD ($)	Mar. 19, 2021 USD ($)	Jan. 25, 2021 USD ($)	Jan. 21, 2021 USD ($)	May 31, 2021	Sep. 30, 2018 Patent	Aug. 31, 2016	Jun. 30, 2016	Jun. 30, 2021 USD ($)	Sep. 30, 2023 USD ($)	Aug. 28, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Oct. 04, 2021 USD ($)
Commitments And Contingencies [Line Items]
Reimbursement payment			$ 14,000,000
Development payments			10,000,000
Other current liabilities											$ 743,856		$ 741,425
Other current assets											14,638		$ 20,188
Pending Litigation | The Securities Class Action
Commitments And Contingencies [Line Items]
Proposed settlement as a loss in accrued expenses											$ 8,400,000			$ 8,400,000
Other current liabilities														$ 900,000
Pending Litigation | Stockholders Derivative Action
Commitments And Contingencies [Line Items]
Payment of settlement amount					$ 500,000
Aventis Pharma SA | License Agreement
Commitments And Contingencies [Line Items]
Agreement entered date									2016-06
Assistance Publique - Hopitaux de Paris ("AP-HP") | License Agreement
Commitments And Contingencies [Line Items]
Agreement entered date							2018-09
Number of patent applications | Patent							3
Assistance Publique - Hopitaux de Paris ("AP-HP") | Private Acer | License Agreement
Commitments And Contingencies [Line Items]
Agreement entered date								2016-08
Relief Therapeutics Holding AG
Commitments And Contingencies [Line Items]
Upfront payment												$ 10,000,000
Relief Therapeutics Holding AG | Termination of Collaboration Agreement
Commitments And Contingencies [Line Items]
Upfront payment												10,000,000
Additional payment due on first year anniversary of termination agreement												1,500,000
Additional payment due on first year anniversary of upfront payment												$ 1,500,000
Percentage of royalty on net sales												10.00%
Percentage of revenue from certain third parties related to licensing												20.00%
Termination of collaboration agreement cap price												$ 45,000,000
Termination of collaboration and license agreement, cap price												45,000,000
Maximum payment for licensing or divestment rights												$ 56,500,000
Relief Therapeutics Holding AG | Collaboration Agreement
Commitments And Contingencies [Line Items]
Upfront non-refundable payment received				$ 1,000,000
Cash payment received				10,000,000
Reimbursement payment			14,000,000	14,000,000
Repayment of outstanding balance of prior loan and interest				$ 4,000,000
Development payments			$ 20,000,000
Net profit split ratio based on territory			60.00%	60.00%
Percentage of royalty revenue received				15.00%
Milestone payment to be received			$ 6,000,000	$ 6,000,000
Relief Therapeutics Holding AG | Collaboration Agreement | First Development Payment
Commitments And Contingencies [Line Items]
Reimbursement payment										$ 10,000,000
Relief Therapeutics Holding AG | Collaboration Agreement | Second Development Payment
Commitments And Contingencies [Line Items]
Potential proceeds from development payments subject to acceptance of new drug															$ 10,000,000
Relief Therapeutics Holding AG | Collaboration Agreement | Maximum
Commitments And Contingencies [Line Items]
Development payments				$ 20,000,000
Relief Therapeutics Holding AG | Collaboration Agreement | Secured Loan
Commitments And Contingencies [Line Items]
Debt instrument, term				12 months
Debt instrument, principal amount				$ 4,000,000
Debt instrument, interest rate				6.00%
Relief Therapeutics Holding AG | Waiver and Agreement
Commitments And Contingencies [Line Items]
Second tranche of development payment, expiry date	Jan. 14, 2022
Relief Therapeutics Holding AG | Waiver and Agreement | Second Development Payment
Commitments And Contingencies [Line Items]
Proceeds from second tranche of development payments subject to new drug application	$ 5,000,000
Proceeds from first tranche of development payments subject to new drug application		$ 5,000,000
Emory University | License Agreement
Commitments And Contingencies [Line Items]
Agreement entered date						2021-05